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Abstract: Solid lipid nanoparticles (SLNs) can be produced by various methods, but most of them 
are difficult to scale up. Supercritical fluid (SCF) is an important tool to produce micro/nanoparticles 
with a narrow size distribution and high encapsulation efficiency. The aim of this work was to 
produce cetyl palmitate SLNs using SCF to be loaded with praziquantel (PZQ) as an insoluble model 
drug. The mean particle size (nm), polydispersity index (PdI), zeta potential, and encapsulation 
efficiency (EE) were determined on the freshly prepared samples, which were also subject of 
Differential Scanning Calorimetry (DSC), Fourier-Transform Infrared Spectroscopy (FTIR), drug 
release profile, and in vitro cytotoxicity analyses. PZQ-SLN exhibited a mean size of ~25 nm, PdI ~ 
0.5, zeta potential ~−28 mV, and EE 88.37%. The DSC analysis demonstrated that SCF reduced the 
crystallinity of cetyl palmitate and favored the loading of PZQ into the lipid matrices. No chemical 
interaction between the PZQ and cetyl palmitate was revealed by FTIR analysis, while the release 
or PZQ from SLN followed the Weibull model. PZQ-SLN showed low cytotoxicity against 
fibroblasts cell lines. This study demonstrates that SCF may be a suitable scale-up procedure for the 
production of SLN, which have shown to be an appropriate carrier for PZQ. 
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1. Introduction 
Research in pharmaceutical nanotechnology has focused on the development of modified 
release nanoparticles for the administration of drugs already used in clinical settings, for which 
several types of drug delivery systems have been proposed in the literature. These systems might 
promote the higher concentration of the active substance at the target sites, reducing the toxicity on 
non-specific tissues. 
Due to their high degree of biocompatibility and limited toxicity in vitro and in vivo [1–3], solid 
lipid nanoparticles (SLNs) are being studied for various administration routes to improve drug 
solubility (and thereby its bioavailability) [2,4] and reduce the risk of adverse side reactions [5,6]. The 
main production methods of SLNs are based on high homogenization and solvent 
evaporation/extraction [7–9]. 
Supercritical fluid (SCF), based on the solvent extraction of oil-in-water (o/w) emulsions using 
supercritical carbon dioxide (CO2), has been proposed to produce micro/nanoparticles with a narrow 
size distribution, better flowability, less residual organic solvent, and with high encapsulation 
efficiency for different types of drugs (e.g., ketoprofen, indomethacin, camptothecin) [10–12]. The 
final material is reported to be a dried powder that facilitates the production of improved liquid or 
solid drug formulations, while the technique is described as environmentally friendly and with the 
potential to be scaled-up [13]. 
In the present work, we describe the development of a new SLN formulation produced by SCF 
to load praziquantel (PZQ) for oral administration. The selected model drug is included in the 
Biopharmaceutical Classification System (BCS) group II, as it shows low solubility and high 
permeability. Due to its low oral bioavailability and bad taste, the classically available formulations 
are unsuitable for children [14,15]. The developed PZQ-SLNs were characterized for their mean 
particle size, polydispersity index, zeta potential, encapsulation efficiency, drug release, and 
cytotoxicity. The solid crystalline lipid matrix loading PLZ, and absence of chemical interactions 
between the drug and the lipid, have been confirmed by Differential Scanning Calorimetry (DSC) 
and Fourier-Transform Infrared Spectroscopy (FTIR), respectively. 
2. Results and Discussion 
Many drugs currently in use in clinics exhibit high lipophilicity, low bioavailability, high 
toxicity, and high sensitivity under some environmental conditions. Given these limitations, drugs 
need to be processed using innovative techniques such as nanoencapsulation. Conventional 
encapsulation techniques use a substantial volume of organic solvents and operate at extremely high 
or low temperatures, resulting in formulations with high polydispersity and high scale-up 
limitations. Due to these disadvantages, an alternative approach was proposed to produce 
nanoparticles by SCF, which is environmentally friendly, easier to scale up, and generates low 
organic residues. In the production of our SLNs, DCM has been used as organic solvent. The 
advantage of SCF is however the possibility of easy recovery of the supercritical solvent after the 
extraction process, just by adjusting the pressure and temperature, being continuously recycled. This 
approach eliminates one of the most expensive steps of conventional extraction processes, which is 
the separation between extracted products and the organic solvent. Also, the handling of large 
amounts of polluting organic solvents poses additional drawbacks with respect to environmental 
control, whether of air quality, liquid effluent, or solid waste. A positive outcome of the efficient 
separation between solute and supercritical solvent is the high purity product that is obtained, as the 
process leaves no solvent residues in the final product. Polymeric nanoparticles, metal nanoparticles, 
nanostructured microparticles, nanoporous materials, and SLNs have been produced using SCF [16]. 
SLNs are superior drug delivery systems attributed to their biocompatibility, modified-release 
properties, and high loading capacity for poorly water-soluble drugs. In this work, PZQ was used as 
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a model drug in SLNs produced by SCF. Blank SLNs (without PZQ) and PZQ-SLNs showed mean 
particle sizes of 24.60 ± 2.45 nm and 23.78 ± 4.52 nm, respectively, without any statistical difference (p 
< 0.05). PdI was also considered in this study as one of the parameters to evaluate the quality of the 
SLN production by SCF. PdI measures the deviation of the autocorrelation function from that of 
dispersions having monodisperse nanoparticles; low PdI values translate to high-quality dispersions. 
Blank SLNs and PZQ-SLNs showed a unimodal distribution, with PdI values of 0.50 ± 0.22 and 0.55 
± 0.12, respectively, which are appropriate for oral administration (i.e., around 0.4 to 0.5). According 
to Danaei et al., a PdI of 0.3 or below in lipid nanoparticle populations is considered to be acceptable 
when intended for parenteral administration [17]. As oral administration does not have the same size 
restrictions, a higher PdI is tolerated by this pathway. Although the last edition of the FDA’s 
“Guidance for Industry” concerning liposome drug products emphasizes the importance of size and 
size distribution as “critical quality attributes (CQAs),” as well as essential components of stability 
studies of these products, the document does not mention the criteria for an acceptable PdI. More 
specific standards and guidelines for the acceptability of product PdI vary among the different 
applications (e.g., food, cosmetic, pharmaceutical, etc.) and different administration routes. 
Zeta potential is a measure of the electrical voltage difference between the surface colloidal 
suspension. It gives information about the stability of a colloidal dispersion; the recommended value 
is higher than +/−30 mV. The ZP values of blank SLN and PZQ-SLN values were of −29.52 ± 0.52 and 
−27.25 ± 0.59, respectively. The negative ZP values are attributed to the negative soybean lecithin that 
acts as surfactant stabilizing SLNs. 
The EE% of PZQ-SLN reached 88.37%, due to the lipophilicity of PZQ. The maximum loading 
capacity obtained for PZQ in SLN was 17.64 mg. 
Xie et al. encapsulated PZQ in SLNs produced by hot homogenization and ultrasonication 
method, reaching an EE% of 62.17±6.53%. Jelowdar et al. produced PZQ-SLNs with EE of 59% and 
confirmed their efficiency in the reduction of echinococcosis cysts in vivo [18]. 
DSC technique has been widely used to obtain information about the purity of the standard 
reference; thermal transitions reflect the physical and chemical processes that are associated with a 
release or absorption of heat. Such transitions include melting, glass transition, polymorph 
conversion, crystallization, desolvation, dehydration, and chemical reactions [19]. Furthermore, DSC 
measures the changes that take place in a material with a change in temperature. Such changes are 
monitored by measuring the heat flow associated with the heating of a sample comparing it to the 
reference while they are subjected to the same controlled temperature program. The DSC 
thermograms of PZQ-SLN, SLN, PZQ, and cetyl palmitate are shown in Figure 1. 















Figure 1. Differential Scanning Calorimetry (DSC) curves of praziquantel solid lipid nanoparticle 
(PZQ-SLN), SLN, PZQ, and cetyl palmitate. 
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The DSC curve of the free PZQ exhibited an endothermic peak of relative intensity at 141.96 °C. 
This value is close to that recorded by Chaud et al. [20] as being the melting temperature of the drug. 
A single endothermic event (ΔH = −158.89 J/g), at 47.84 °C, was recorded for the bulk cetyl palmitate. 
The melting of this lipid may occur at different temperatures depending on the type of polymorphs 
present. Low temperatures (e.g., close to 40 °C) are attributed to the presence of α-form, followed by 
the metastable β’-form, and then by the most stable β-form at temperatures close to 50 °C. Waxes as 
cetyl palmitate are commonly recrystallized in the metastable β’-form. During the cooling of the 
melted lipid, the recrystallization of the lipid matrix occurs for the solidification of the core and 
formation of SLNs. These changes result in phase transitions of the structural order, such as 
crystalline state and enthalpy, due to the formation of a new structure promoted by the method of 
production. This new structure may also be the reason for values of PdI obtained for the SLN 
dispersions. When analyzing the DSC curves of SLNs, it was shown that the production procedure 
provided a slightly higher temperature shift (Tpeak = 52.64 °C) with enthalpy reduction (ΔH = −80.04 
J/g) when compared to bulk cetyl palmitate, which translates the formation of solid, yet less 
crystalline, SLN matrices. 
In PZQ-SLN thermograms, a new DSC curve profile has been recorded, exhibiting a set of higher 
intensity peaks at 124.95 °C, and an even more significant reduction for enthalpy (ΔH = −38.80 J/g). 
The thermal behavior of the loaded SLNs, mainly in the enthalpy values, suggests that a large 
polymorphic transformation is influencing these changes, attributed to the use of supercritical fluid 
as the production methodology, providing significant structural changes and causing a decrease in 
the degree of SLN crystallinity. The decrease of enthalpy of the PZQ-SLNs and absence of the PZQ 
suggest, respectively, that the drug is loaded in the particles and that it is solubilize in the selected 
solid lipid. The low degree of crystallinity contributes to increase the loading of the lipid matrices 
with PZQ, and thereby high EE%. The complete solubilization of the drug in the melted cetyl 
palmitate of PZQ-SLN was confirmed by suppression of the PZQ peak at 141.96 °C in the thermogram 
of the drug-loaded particles. 
FTIR allows for the identification of functional groups present in the materials. The observation 
of the vibration spectrum of the encapsulated drug allows evaluating the type of interaction that 
occurs between the drug and the matrix material, since the vibrations of the atoms involved in this 
interaction can suffer changes of frequency and intensity. FTIR spectra of soybean lecithin, cetyl 
palmitate, PZQ, PZQ-SLN, and SLN are shown in Figure 2. 






































Figure 2. Fourier-Transform Infrared Spectroscopy (FTIR) spectra of (A) soybean lecithin; (B) cetyl 
palmitate; (C) PZQ; (D) PZQ- SLN; and (E) SLN. 
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For PZQ, the wide band in the region 3600–3400 cm−1 indicates a characteristic stretching of the 
O–H group and can be attributed to the presence of water molecules. It shows major peaks from the 
groups of molecules such as carbonyl stretch vibrations –C=O (1630 cm−1), –CH, –CH2, –CH3 (2900–
3000 cm−1), and C–N stretch vibrations (1000–1350 cm−1). Similar results have been reported by Chaud 
et al. [21]. Other characteristic bands occur between 1244 and 1066 cm−1 attributed to the axial 
deformations C–N, symmetrical angular plane C–H cyclic structure at 1411 cm−1. The FTIR results for 
PZQ are in agreement with those described in the literature [22,23]. Soybean lecithin (A) showed 
peaks for –CH, –CH2, –CH3 elongations (2850–2850 cm−1), carbonyl stretch vibrations –C=O (1700–
1734 cm−1), stretching of C–O (1025–1244 cm−1), and OH– stretching vibrations (3100–3418 cm−1), 
which were broad. The peak at 2217 is associated with the formation of a carbon–nitrogen bond 
between PZQ and soy lecithin [24], which appears only in D (Figure 2). The results demonstrate that 
there was no chemical interaction between the drug and the soybean lecithin because their spectra 
shape and position were not significantly different. The formulation of SLN (E) and SLN loaded PZQ 
(D) showed peaks resulting from the simple superposition of their separated components in the FTIR. 
The spectral analysis indicated that PZQ-SLN (D) specific functional groups on the surface of the 
nanoparticles exhibit almost the same chemical characteristics as cetyl palmitate (B) and the trapped 
drug exhibits its main characteristic peaks. The present study suggests that there were no molecular 
interactions that could modify the chemical structure of PZQ. 
The in vitro behavior of the isolated PZQ drug release and PZQ-SLN was investigated using a 
dialysis membrane in phosphate buffer solution at pH 7.0 (37 ± 0.2 °C). Figure 3 shows the obtained 
release profiles. 
 
Figure 3. In vitro drug release profile of free PZQ and PZQ-SLN. 
PZQ exhibited a maximum release rate of 3.85% drug in 8 h, while the release profiles of PZQ-
SLN indicated a release of 7.64%. There was a statistical difference between the evaluated samples, 
demonstrating that a release of the PZQ from SLN occurred in a more controlled pathway when 
compared to the isolated PZQ. The release modelling was analyzed by finding the R2 value for each 
kinetic model, namely, Baker and Lonsdale, Peppas, Hixon and Crowell, Higuchi, Square Root, First 
Order, and Weibull. The parameters corresponding to the release data obtained. The parameters 
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Table 1. Coefficient of in vitro release of different mathematical models for formulations PZQ, SLN, 
and PZQ-SLN. 
 Square r Value (r2) 
 PZQ-SLN PZQ 
Mathematical Models   
Baker and Lonsdale  0.8851 −0.4559 
Korsmeyer-Peppas 1.0 0.8215 
Hixon and Crowell  0.9999 −2.2413 
Higuchi, Square Root 0.8881 −0.4665 
First Order  0.9999 −2.2292 
Weibull  1.0 1.0 
The Weibull model can be applied successfully on almost all types of release curve and 
exponentially relates the fraction of the released drug. The Weibull equation expresses the cumulative 
amount of drug as a function of time and should be applied to the data of the first 63.2% drug release. 
On the other hand, the Korsmeyer-Peppas model takes into account that the mechanism of drug 
release does not follow Fick’s law and follows an anomalous behavior described by Equation (1). 𝑀𝑀 =  𝑘𝑡  (1) 
where Mt is the amount of drug released in a given time t, M∞ is the amount of drug released at an 
infinite time, k is the release kinetic constant, and n is the release exponent. The value of n is related 
to the geometric form of the release system and determines the release mechanism. The Kornmeyer-
Peppas model is generally used to analyze the release of a drug from a matrix when it is not well 
known or when one or more types of phenomena are involved. 
PZQ-loaded SLNs presented release kinetics following two mathematical models, being 
indicative of the structural heterogeneity of the formulation, which possibly demonstrates the SLN 
formation coated by multiple layers of surfactant, also demonstrated by the PdI obtained for the 
dispersion. The lipid used for the preparation of SLNs plays a key role in the design of release 
kinetics, as the lipid is responsible for the encapsulation of the drug in the matrix of the particles. Our 
results suggest that cetyl palmitate used in the formulation forms a polymorphs structures which 
control the drug outlet of the SLNs. However, as the drug dissolves, the porosity of the matrix 
increases, so that the drug can be released. In addition, the use of Tween®20 as surfactant, causes the 
compacted systems to be dissolved by progressive erosion, releasing PZQ. Tween®20 is able to 
promote drug release because of increased contact of the drug in water, promoting a greater 
dispersion of the drugs, besides favoring the release of the same by disintegration. 
In vitro cytotoxicity was performed using human fibroblast L2929 as a cellular model. As 
reported in the scientific literature, although the lipids and surfactants used for the production of 
SLNs are of GRAS status, the cytotoxicity of these raw materials is dependent on the concentration 
and type of cell model. The administration route is also decisive to set the limits of acceptance. Besides 
the raw materials, the cytotoxicity of SLNs is dependent on the size and surface properties, as well as 
on the concentration of the particles in contact with the cells. The cytotoxicity profile of both blank 
and PZQ-SLNs should be obtained. The data are shown as a percent of cellular viability (Figure 4). 
The cell viability results demonstrate that free PZQ did not kill normal human fibroblasts. Indeed, 
cellular viability was greater than 88%. Moreover, blank SLNs (97.78%) and PZQ-SLNs (86.77%) also 
did not show any toxicological activity. The results indicate the safety and biocompatibility of both 
SLNs and PZQ-SLNs with fibroblasts cells. Any cytotoxic effect of particles can be due to their 
adherence to the cell membrane, particle internalization and/or degradation of products in the cell 
culture medium or inside the cells. However, the susceptibility of different cell types can be different 
for different particulate carriers. Because the SLNs contain natural lipids, they should be well-
tolerated by living organisms [25]. 



























Figure 4. Effect of praziquantel, SLNs, and PZQ-SLNs supercritical in the evaluation of the viability 
of human L929 fibroblasts determined by the MTT assay after 24 h of incubation. The negative control 
(C) was treated with the vehicle used to dilute the drug (DMSO 5%). The data correspond to the mean 
± SEM of four independent experiments. 
3. Materials and Methods 
3.1. Materials 
PZQ was provided by Henrifarma® (Cambuci, São Paulo, Brazil). Soybean lecithin (Lipoid® S75) 
was purchased from Lipoid GmbH (Ludwigshafen, Germany). Cetyl palmitate was donated as a gift 
from Croda (Campinas, Brazil). All other reagents were bought from Sigma-Aldrich (Sintra, 
Portugal). Double-distilled water was used after filtration in a Millipore® system (home supplied). 
3.2. Production of SLN 
The oil phase, composed of solid lipid (cetyl palmitate, 150 mg), drug (PZQ, 20 mg), surfactant 
(Tween 20, 100 mg), and co-surfactant (soy lecithin, 150 mg), was solubilized in dichloromethane (50 
mL) using magnetic stirring (Thermo Scientific Cimarec Stirring Hot Plate, 7 × 7 Ceramic; 120 VAC) 
for 30 min. SLN were then placed in a continuous extraction method from Waters Corporation (SAS-
RESS Combined System, Pittsburgh, PA, USA). The method consisted on the introduction of the 
organic solution into an extraction column from the top at a constant flow rate of supercritical CO2 
(at a constant pressure of ~80 bar and 35 °C) as a countercurrent. The residence time required for SLN 
production was 2 min. The solvent-borne CO2 was carried out in the extraction column for solvent 
recycling, and SLNs were then collected in the vessel was collected for further characterization. The 
equipment allows the production of size batches from 100 mL to 5000 mL. The batch size of our PZQ-
SLNs was 100 mL. 
3.3. Mean Particle Size, Polydispersity Index, and Zeta Potential 
The mean particle size (z-Ave), polydispersity index (PdI), and zeta potential (ZP) of the SLNs 
were determined by photon correlation spectroscopy (Malvern Zetasizer, Nano Z-S; Malvern 
Instruments, Worcestershire, UK). Measurements were performed at a 90-degree angle at 25 °C. 
3.4. Encapsulation Efficiency (EE) and Loading Capacity (LC) 
The encapsulation efficiency (EE) and the loading capacity (LC) of the PZQ into SLNs were 
determined indirectly, by measuring the concentration of free, unloaded PZQ in the aqueous medium 
of the nanoparticles. Briefly, approximately 1 g of PZQ-SLNs was weighed and ultra-centrifuged for 
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40 min at 4 °C at 16,000 rpm (Biofuge Strato, Hong Kong). The amount of non-loaded PZQ in the 
supernatant was determined using ultraviolet (UV) spectrophotometry with the detection 
wavelength set at 264 nm [15]. EE (%) and LC (%) were calculated in triplicate using Equations (2) 
and (3) [2,4]. EE %  =  Total amount of PZQ − PZQ in supernatantTotal amount of PZQ × 100 (2) 
LC % =   Total amount of PZQ − PZQ in supernatantTotal amount of PZQ  × 100 (3) 
3.5. Differential Scanning Calorimetry (DSC) 
The analysis of the solid state of the lipid matrices (SLNs) was performed using a DSC TA 2920 
(Newcastle, DE, USA). The samples were placed in the hermetic aluminum pans, and the experiments 
were performed under a nitrogen gas flow at a heating rate of 10 °C/min over a temperature range of 
25–350 °C [7]. 
3.6. Fourier-Transform Infrared Spectroscopy (FTIR) 
The Fourier-transform infrared spectroscopy (FTIR) spectra of the SLNs, PZQ, and PZQ-SLNs 
were recorded using potassium bromide discs on a Nicolet 5 SXC FTIR Spectrophotometer (Madison, 
WI, USA). The potassium bromide discs were prepared by compressing the corresponding powder. 
3.7. In Vitro Drug Release Studies 
The in vitro drug release assay was determined by the dialysis bag method with some 
adaptations [15]. The equivalent of 2 mL of the PZQ-SLN formulation (described in 3.2) and 2 mL of 
PZQ solution (0.8 mg PZQ dissolved in 2 mL water) were placed in independent dialysis bags (L 50 
mm x W 25 mm x D 16 mm, InLab, São Paulo, Brazil). Both dialysis bags were submerged in 10 mL 
water and 40 mL phosphate buffer solution at 37 ± 0.2 °C, pH 7.0 ± 0.3 and under constant magnetic 
stirring (200 rpm). Then, at pre-determined time-intervals (5–180 min), a volume of 200 μL of the 
release medium was collected, filtered through a membrane of 0.45 μm pore size, and analyzed in a 
UV spectrophotometer (UV-Vis Spectrophotometer, Model UV2600 Shimadzu Corporation, Tokyo, 
Japan). The same volume of fresh phosphate buffer solution at the same temperature was added 
immediately to keep the release volume constant and guarantee sink conditions. The method was 
validated using the spectrophotometry technique in the ultraviolet (UV) region according to 
Resolution 899 in 2003 by the National Agency of Sanitary Surveillance (ANVISA). The drug release 
studies were performed in triplicate. Finally, the best model for evaluating the rate of drug release 
was determined using the Sigmaplot software (Systat Software Inc., San Jose, CA, USA). 
3.8. Cell Viability Assay in L929 Cells 
The human fibroblast cell line L929 was used in testing the free PZQ, SLNs, and PZQ-SLNs at a 
concentration of 30 μg/mL each, based on the ISO 10993-5 [26]. L929 cells were seeded in 96-well 
culture plates (2 × 10⁴ cells/well) and cultured in DMEM media containing NaHCO3, ampicillin, 
streptomycin, and supplemented with 10% fetal bovine serum. After 24 h of treatment, the wells were 
washed, and the cells were exposed to 10 μL of the 5 mg/mL 3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-
diphenyltetrazolium bromide (MTT) solution, which was left to react for 3 h [27]. The MTT solution 
was then removed, and 80 μL of dimethylsulfoxide (DMSO) was added to each well. The plates were 
shaken gently for 10 min, and then the absorbance was measured in an ELISA microplate reader at 
570 nm. 
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3.9. Statistical Analyses 
The data obtained were expressed as the mean ± standard error of the mean (SEM), and the 
differences between the experimental groups were evaluated using one-way analysis of variance 
(ANOVA) followed by the Tukey’s post hoc test. Significant values with p < 0.05 were considered. 
All statistical analyses were performed using the GraphPad Program (Intuitive Software for Science, 
San Diego, CA, USA). 
4. Conclusions 
The production of PZQ-SLNs by SCF shows promising results when using cetyl palmitate as 
solid lipid. The method produced small-sized SLN, of polydispersity appropriate for oral 
administration, with a modified release profile and non-toxic against fibroblasts. A high 
encapsulation efficiency was reached for praziquantel in cetyl palmitate SLNs. 
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